COMBINING

UNCOMMON EXPERTISE

WITH PROPRIETARY DATA
TO DRIVE UNIQUE INSIGHT 

IPD Analytics identifies, projects, and quantifies the impact of competitive-landscape shifts in the pharmaceutical and biologic market to offer: 

   

 

  • Industry-leading drug life-cycle analysis

  • Clinical, formulary, procurement, and inventory-control insights for payers, providers, and suppliers

 

  • Brand and generic market impact forecasts

 

  • Pharmaceutical coding and reimbursement information

 

THE INDUSTRY LEADER

AN INDEPENDENT, THIRD-PARTY SOURCE

Map.png
Asset 2.png
Asset 2.png
Asset 2.png
Funnel.png
Head.png
LOE Pyriamid.png
Arrow.png

We take data from thousands of sources, combine it with proprietary research, and work to normalize, analyze, and summarize... 

Untitled-2.png

With a unique team of experts, including:

 

Former Federal Circuit Patent Clerks and Litigators

Payor and Provider
Clinical Pharmacists

Brand and Generic Financial Forecasters from
Major Manufacturers

PhD Scientists with Pharmacy and Bioscience Backgrounds


Team of Researchers and Patent Searchers Utilizing Proprietary Data Aggregation Tools

We develop the
foundation that powers our solutions:

loss-of-exclusivity

timing

And provide meaningful, tailored insights for
specific use cases:

 

Key Litigation Updates & Analysis

Critical Headlines & 

Day-by-day Trial Updates


Drug & Disease-Class Reviews

 

Formulary Planning Guidance
 

Loss-of-Exclusivity and
Market-Impact Forecasts

Analog Library with Accompanying Qualitative Analysis

Pipeline-Planning Tools
 

Coding & Reimbursement Insights


Drug-Price Tools

Scenario Analysis


We deliver these insights in multiple, easily consumable formats:

To serve stakeholders and institutional investors across the pharmaceutical industry:

Platform

Email Alerts

Direct Consultations

Podcast Episodes

Reports

Data Downloads

Manufacturers:

Brand Manufacturers

Generic Manufacturers

Specialty Drug Manufacturers

Active Ingredient Manufacturers

 

Institutional Investors:

Investment Managers

Hedge Funds

Mutual Funds

Sovereign Funds

Pension Funds

 

THE INDUSTRY LEADER

AN INDEPENDENT, THIRD-PARTY SOURCE

Since 2002, IPD Analytics has offered solutions that: 

  • Deliver compelling insight and unique data assets to solve complex, multi-layered problems   

  • Enable efficiency and transparency in an opaque pharmaceutical market

  • Offer a comprehensive look at the past to help predict future market shifts

Map.png
Funnel.png
Head.png
Asset 181.png

We take data from thousands of sources, combine it with proprietary research, and work to normalize, analyze, and summarize... 

Untitled-2.png

With a unique team of experts, including:

Former Federal Circuit Clerks, Patent Attorneys, and Litigators

Payer and Provider
Clinical Pharmacists

Brand and Generic Financial Forecasters from
Major Manufacturers

PhD Scientists with Pharmacy and Bioscience Backgrounds


Team of Researchers and Patent Searchers Utilizing Proprietary Data-Aggregation Tools

We develop the
foundation that powers our solutions:

loss-of-exclusivity

timing and innovative, product-launch tracking

And provide meaningful, tailored insights for
specific use cases:

Drug Litigation Updates & Analysis

Critical Headlines & 

Day-by-Day Trial Updates


Drug & Disease-Class Reviews

 

Formulary Planning Guidance
 

Loss-of-Exclusivity and
Market-Impact Forecasts

Clinical Pipeline Tracking Tools
 

Coding & Reimbursement Solutions


Drug-Price and Rebate Monitoring Tools

Limited Distribution, Formulary Coverage, Clinical Criteria, and Therapy Cost Analysis

Brand, Generic, and Biosimilar Launch Forecasts

Budget Impact Models


We deliver these insights in multiple, easily consumable formats:

Untitled-1.png

To serve stakeholders and institutional investors across the pharmaceutical industry:

Online Platform

Email Alerts

Phone Consultations

Podcast Episodes

Reports

Data Downloads

Manufacturers:

Brand Manufacturers

Generic Manufacturers

Specialty-Drug Manufacturers

Active-Ingredient Suppliers

 

Payors, Providers, & Suppliers:

Payors

Health Systems

Wholesalers

Specialty & Retail Pharmacies

Long-Term Care Facilities

IDNs

GPOs

PBMs

Institutional Investors:

Investment Managers

Hedge Funds

Mutual Funds

Sovereign Funds

Pension Funds

Private Equity

 

OUR SOLUTIONS

IPD Analytics provides actionable insights to drive decisions.

We offer subscription-based access to our proprietary platforms, consultations, real-time email alerts, comprehensive reports, data downloads, podcast episodes, and more.

Pharmaceuticals  |  Biotech  |  Biosimilars

Global Life-Cycle Solutions

Clinical Pharmacy Solutions

Market Forecasting Solutions

OTHER INDUSTRIES

 

OUR SUBSCRIBERS

IPD Analytics offers tech-enabled solutions to stakeholders across the pharmaceutical landscape.

 
 

PODCAST 

IPD's Drug & Clinical Review:

The Premier Podcast for Drug Intelligence and Management Strategy

Within each episode, IPD's Executive Clinical Pharmacy Team discusses:

  • Drug pipeline intelligence and clinical strategy surrounding loss of exclusivity, high-cost and complex drugs, formulary planning, and pharmacy and therapeutics management

  • Impactful generic, brand, and biosimilar launches coming
    down the pipeline 

 

  • Strategies to improve outcomes, lower pharmacy spend, and optimize formulary design

 

  • Popular questions frequently asked by payers, providers, and manufacturers around the country

NEWSROOM

FEATURED

REPORT FEATURE
April 21, 2020

National trends in prescription drug expenditures and projections for 2021

Purpose

To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2021 in the United States, with a focus on the nonfederal hospital and clinic sectors.

Methods

Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2021 were reviewed—including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, generics, coronavirus disease 2019 (COVID-19) pandemic influence, and specialty drugs. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2021 were based on a combination of quantitative analyses and expert opinion.

SEE MORE

ARTICLE FEATURE
April 21, 2020

Further Dissecting the Launch of Adalimumab Biosimilars in the US

As we inch closer to the January 2023 date for the launch of the first US adalimumab biosimilar, industry watchers are more closely scrutinizing which company, if any, will have a competitive advantage in this lucrative marketplace.

Just to reset, the series of settlements signed by AbbVie currently puts Amgen’s Amjevita® first to be released, followed by several others according to the schedule we first published in May 2019.

A few developments have occurred since then, primarily the subsequent FDA approval of Hulio®, Hadlima®, and Abrilada®. Momenta was acquired by Johnson & Johnson in October 2020 and is no longer a separate entity or operating in the biosimilar business. But Coherus filed for approval in December 2020, and Alvotech and its partner Teva filed in November 2020. Celltrion, which completed its phase 3 trial, is on the verge of filing for approval, and Fresenius Kabi may join the crowd in filing this year as well.

SEE MORE

ARTICLE FEATURE

October 8, 2020

EY Announces Howard Krass founder and CEO of IPD Analytics, LLC as Entrepreneur Of The Year® 2020 Florida Award Winner

Ernst & Young LLP (EY US) today announced that Howard Krass of IPD Analytics, LLC was named an Entrepreneur Of The Year® 2020 Florida Award winner. The Entrepreneur Of The Year Awards program is one of the preeminent competitive awards for entrepreneurs and leaders of high-growth companies. Howard was recognized for his excellence in innovation, societal impact, commitment to building a values-based company, financial performance, and overall leadership. Howard Krass was selected by an independent judging panel. The award was announced through the program’s first-ever virtual awards gala, hosted by Deborah Norville, anchor of Inside Edition, on October 8, 2020. To watch the replay, visit the Florida program website.

SEE MORE

 
 

TALK TO US...

To learn more about our solutions, podcasts, or simply to connect, fill in your contact details.
arrow&v
If you'd like to learn more about one or more of our solutions, please specify: